RUTO STOOPS TO DEFEND MILLION-SHILLING FASHION
OWONO FACES MAXIMUM BAN AFTER DE MIGUEL'S DEATH
NIS BEHIND FAKE POLLS, GACHAGUA CLAIMS
DON'T DRAG MY NAME FOR CLOUT, JALANG'O WARNS BAHATI
JUMWA REJOINS UDA, SPARKS SPY SPECULATIONS
RUTO, SIFUNA DRAW IN 2027 PRESIDENTIAL POLL
CARRICK PAYS PRICE FOR UNITED CRISIS
MARIGA CHALLENGES FKF OUSTER, VOWS TO FIGHT ON
DANCEHALL ROCKS KANYARI'S CHURCH
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions, although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences, a drug called lenacapavir, could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take.
“This really has the possibility of ending HIV transmission,” said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research.
Condoms help guard against HIV infection if used properly but what’s called PrEP regularly using preventive medicines such as the daily pills or a different shot given every two months is increasingly important. Lenacapavir’s six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills.
Comments (0)
No comments yet. Be the first to comment!